Drug Profile
Fotagliptin - Chongqing Fochon Pharmaceutical
Alternative Names: FCN-005; Fotagliptin benzoate; Futagliptin benzoic acidLatest Information Update: 21 Jul 2022
Price :
$50
*
At a glance
- Originator Chongqing Fochon Pharmaceutical
- Class Antihyperglycaemics; Nitriles; Piperidines; Triazines
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 14 Jul 2022 Phase-III clinical trials in Type 2 diabetes mellitus in China (PO), as of July 2022 (Shenzhen Salubris Pharmaceuticals)
- 15 Feb 2022 Fotagliptin is still in phase II development for Type 2 diabetes mellitus in China (Chongqing Fochon Pharmaceutical website, February 2022)
- 02 Apr 2019 Salubris Pharmaceuticals initiates enrolment in a phase I trial for Type 2 diabetes mellitus in China (ChiCTR1900022104)